Multiple sclerosis: Treating symptoms, and other general medical issues

Myla D. Goldman, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic

Jeffrey A. Cohen, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic

Robert J. Fox, MD
Medical Director, Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Francois A. Bethoux, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic

Address: Myla D. Goldman, MD, Mellen Center, U10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail goldmam1@ccf.org

Dr. Fox has indicated that he has served as a cosultant for the Acorda Therapeutics, Biogen Idec, Genetech, Merck, Questcor, Serono, and Teva Neuroscience corporations and on the speaker’s bureaus of the Biogen Idec and Genentech corporations.

Dr. Bethoux has indicated that he has received research funding from and served on the speakers bureau of the Medtronic corporation.

This work was supported by grants from the Potiker Fellowship (MDG), National MS Society (FP 1521-A-1 to MDG, RG 33548A2 to RJF), National Institutes of Health (NINDS K23 NS 47211 to RJF), and the Nancy Davis Center Without Walls (JAC and RJF).

Myla D. Goldman, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic

Jeffrey A. Cohen, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic

Robert J. Fox, MD
Medical Director, Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Francois A. Bethoux, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic

Address: Myla D. Goldman, MD, Mellen Center, U10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail goldmam1@ccf.org

Dr. Fox has indicated that he has served as a cosultant for the Acorda Therapeutics, Biogen Idec, Genetech, Merck, Questcor, Serono, and Teva Neuroscience corporations and on the speaker’s bureaus of the Biogen Idec and Genentech corporations.

Dr. Bethoux has indicated that he has received research funding from and served on the speakers bureau of the Medtronic corporation.

This work was supported by grants from the Potiker Fellowship (MDG), National MS Society (FP 1521-A-1 to MDG, RG 33548A2 to RJF), National Institutes of Health (NINDS K23 NS 47211 to RJF), and the Nancy Davis Center Without Walls (JAC and RJF).

Myla D. Goldman, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic

Jeffrey A. Cohen, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic

Robert J. Fox, MD
Medical Director, Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Francois A. Bethoux, MD
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic

Address: Myla D. Goldman, MD, Mellen Center, U10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail goldmam1@ccf.org

Dr. Fox has indicated that he has served as a cosultant for the Acorda Therapeutics, Biogen Idec, Genetech, Merck, Questcor, Serono, and Teva Neuroscience corporations and on the speaker’s bureaus of the Biogen Idec and Genentech corporations.

Dr. Bethoux has indicated that he has received research funding from and served on the speakers bureau of the Medtronic corporation.

This work was supported by grants from the Potiker Fellowship (MDG), National MS Society (FP 1521-A-1 to MDG, RG 33548A2 to RJF), National Institutes of Health (NINDS K23 NS 47211 to RJF), and the Nancy Davis Center Without Walls (JAC and RJF).